Switch theme
Sign up to access all valuation multiples
Schott Pharma AG & CO KGaA caters to the pharma, biotech and life science industry by providing containment solutions and delivery systems for injectable drugs. Its segments include; Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of the revenue is generated from Drug Containment Solutions segment which includes products like vials, cartridges and ampoules for safe drug containment. Geographically, the company generates revenue from Europe, Middle East, Africa (EMEA), Asia and South Pacific, North America and South America.
1884
4.7K+
LTM Revenue $1.1B
LTM EBITDA $301M
$4.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Schott Pharma has a last 12-month revenue (LTM) of $1.1B and a last 12-month EBITDA of $301M.
In the most recent fiscal year, Schott Pharma achieved revenue of $1.1B and an EBITDA of $295M.
Schott Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Schott Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $381M | XXX | $362M | XXX | XXX | XXX |
| Gross Margin | 34% | XXX | 34% | XXX | XXX | XXX |
| EBITDA | $301M | XXX | $295M | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $222M | XXX | $213M | XXX | XXX | XXX |
| EBIT Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $172M | XXX | $168M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Schott Pharma's stock price is EUR 28 (or $32).
Schott Pharma has current market cap of EUR 4.2B (or $4.8B), and EV of EUR 4.3B (or $4.8B).
See Schott Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.8B | $4.8B | XXX | XXX | XXX | XXX | $1.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Schott Pharma has market cap of $4.8B and EV of $4.8B.
Schott Pharma's trades at 4.4x EV/Revenue multiple, and 16.2x EV/EBITDA.
Equity research analysts estimate Schott Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Schott Pharma has a P/E ratio of 27.7x.
See valuation multiples for Schott Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV (current) | $4.8B | XXX | $4.8B | XXX | XXX | XXX |
| EV/Revenue | 4.3x | XXX | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | 16.0x | XXX | 16.2x | XXX | XXX | XXX |
| EV/EBIT | 21.8x | XXX | 22.3x | XXX | XXX | XXX |
| EV/Gross Profit | 12.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | 27.7x | XXX | 28.1x | XXX | XXX | XXX |
| EV/FCF | 85.8x | XXX | 62.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSchott Pharma's last 12 month revenue growth is 10%
Schott Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $32K for the same period.
Schott Pharma's rule of 40 is 37% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Schott Pharma's rule of X is 52% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Schott Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | 7% | XXX | XXX | XXX |
| Rule of 40 | 37% | XXX | 37% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $32K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Ansell | XXX | XXX | XXX | XXX | XXX | XXX |
| Polymed | XXX | XXX | XXX | XXX | XXX | XXX |
| Farmaceutica Remedia | XXX | XXX | XXX | XXX | XXX | XXX |
| Etropal | XXX | XXX | XXX | XXX | XXX | XXX |
| Sopharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Schott Pharma acquired XXX companies to date.
Last acquisition by Schott Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Schott Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Schott Pharma founded? | Schott Pharma was founded in 1884. |
| Where is Schott Pharma headquartered? | Schott Pharma is headquartered in Germany. |
| How many employees does Schott Pharma have? | As of today, Schott Pharma has 4.7K+ employees. |
| Is Schott Pharma publicy listed? | Yes, Schott Pharma is a public company listed on ETR. |
| What is the stock symbol of Schott Pharma? | Schott Pharma trades under 1SXP ticker. |
| When did Schott Pharma go public? | Schott Pharma went public in 2023. |
| Who are competitors of Schott Pharma? | Similar companies to Schott Pharma include e.g. Ansell, Polymed, Farmaceutica Remedia, Etropal. |
| What is the current market cap of Schott Pharma? | Schott Pharma's current market cap is $4.8B |
| What is the current revenue of Schott Pharma? | Schott Pharma's last 12 months revenue is $1.1B. |
| What is the current revenue growth of Schott Pharma? | Schott Pharma revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Schott Pharma? | Current revenue multiple of Schott Pharma is 4.3x. |
| Is Schott Pharma profitable? | Yes, Schott Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Schott Pharma? | Schott Pharma's last 12 months EBITDA is $301M. |
| What is Schott Pharma's EBITDA margin? | Schott Pharma's last 12 months EBITDA margin is 27%. |
| What is the current EV/EBITDA multiple of Schott Pharma? | Current EBITDA multiple of Schott Pharma is 16.0x. |
| What is the current FCF of Schott Pharma? | Schott Pharma's last 12 months FCF is $56.2M. |
| What is Schott Pharma's FCF margin? | Schott Pharma's last 12 months FCF margin is 5%. |
| What is the current EV/FCF multiple of Schott Pharma? | Current FCF multiple of Schott Pharma is 85.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
